Acadia Healthcare’s Price Target Raised to $20 as Q4 Revenue Hits $821.5M
Barclays lifted Acadia Healthcare’s price target to $20 from $14, maintaining an Equal Weight rating after the company reported Q4 revenue of $821.5 million, up 6.1% year-over-year. Adjusted EBITDA reached $99.8 million while adjusted net income was $6.1 million, and 2026 revenue is guided to $3.37–$3.45 billion.
1. Barclays Raises Price Target
Barclays analyst Andrew Mok increased Acadia Healthcare’s price objective to $20 from $14 while retaining an Equal Weight rating, reflecting confidence in the company’s growth trajectory despite a conservative stance on valuation.
2. Fourth-Quarter Financial Results
Acadia reported Q4 2025 revenue of $821.5 million, a 6.1% increase year-over-year, with same-facility revenue up 4.4%. The firm recorded a net loss of $13.02 per diluted share driven by a $996.2 million goodwill impairment, while adjusted net income was $6.1 million and adjusted EBITDA reached $99.8 million after a $52.7 million reserve adjustment.
3. Capacity Expansion and 2026 Guidance
The company added 181 licensed beds in Q4 and 1,089 beds across 2025, supporting its forecasted revenue range of $3.37–$3.45 billion for 2026. Adjusted EPS is projected between $1.30 and $1.55 as volume growth and facility expansions drive future performance.